DIRS.INFO The most relevant business & tech news

☆ Futures rise on Meta forecast ahead of key earnings, economic data
▼ + stars: | 2023-04-27 | by ( ) www.reuters.com time to read: +3 min

SummarySummary Companies Futures up: Dow 0.26%, S&P 0.42%, Nasdaq 0.70%April 27 (Reuters) - U.S. stock index futures rose on Thursday as an upbeat forecast from Meta Platforms lifted social media stocks, with investors looking forward to big-ticket earnings and key economic data. Shares of social media platforms Snap Inc (SNAP.N) and Pinterest Inc (PINS.N) rose 3.4% and 2.8%, respectively. Meta is the second best performer among the S&P 500 stocks with a 74% gain so far this year, next only to Nvidia Corp (NVDA.O). Analysts expect first-quarter earnings to have fallen 3.2% year-over-year for S&P 500 (.SPX) companies versus a 5.1% decline forecast earlier, according to Refinitiv data on Wednesday. ET, Dow e-minis were up 88 points, or 0.26%, S&P 500 e-minis were up 17.25 points, or 0.42%, and Nasdaq 100 e-minis were up 90.25 points, or 0.7%.

☆ Eli Lilly raises annual profit forecast on strength of diabetes drug
▼ + stars: | 2023-04-27 | by ( ) www.reuters.com time to read: +1 min

Companies Eli Lilly and Co FollowApril 27 (Reuters) - Eli Lilly and Co (LLY.N) raised its full-year profit forecast on Thursday, betting on the approval of its diabetes drug, tirzepatide, for the treatment of obesity expected later this year. Lilly now expects adjusted 2023 earnings of $8.65 to $8.85 per share, compared with its prior forecast of $8.35 to $8.55. Analysts were expecting annual profit of $8.45 per share, according to Refinitiv estimates. Sales of the drug, sold under the brand name Mounjaro for diabetes, came in at $568.5 million, beating estimates of $422.5 million, according to an average of four analysts polled by Refinitiv. Reporting by Bhanvi Satija in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

☆ Eli Lilly races rising obesity expectations
▼ + stars: | 2023-04-27 | by ( ) www.reuters.com time to read: +2 min

NEW YORK, April 27 (Reuters Breakingviews) - The race is on between Mounjaro’s growth and investors’ burgeoning hopes. The drug made by Eli Lilly (LLY.N), which was approved in May to treat diabetes, reaped an astonishing $569 million of revenue in the first quarter less than a year after it was approved for sale. The results encouraged Lilly to raise its annual profit guidance by 3.5%. The pharmaceutical firm also unveiled alongside its earnings release on Thursday that the drug had its second successful large clinical trial against obesity. With another successful trial under Lilly’s belt, Mounjaro is likely to receive an official green light from the U.S. Food and Drug Administration for use in obesity, and more insurers will subsidize the cost.

Bischoff died on Tuesday of natural causes, a close relative, who asked not to be named, told Reuters on Wednesday. A former chairman of Lloyds Banking Group (LLOY.L), Citigroup (C.N) and more recently JP Morgan Securities (JPM.N), Bischoff had also been CEO of Schroders (SDR.L). Robert Swannell, former chairman of Marks & Spencer, who worked with Bischoff for 33 years at Schroders and later Citi, said he would profoundly mourn his friend and colleague. The deal was hailed as a huge success for Bischoff's leadership team, having started with a business worth just a fraction of the 1.3 billion pounds price Citi later paid. He returned to JP Morgan as chairman of JP Morgan Securities the same year.

☆ Here’s our April rapid-fire update on the stocks in Cramer’s Charitable Trust
▼ + stars: | 2023-04-26 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +10 min

When AMD reports earnings next week, we'll be looking for signs that its integration of Xilinx has proven a success. Amazon (AMZN): Investors will be looking closely at profit margins and the growth rate at cloud unit Amazon Web Services when the company reports earnings after the closing bell Thursday. After a disappointing fourth-quarter print, we're hoping to see evidence that CEO Jim Farley has righted the ship. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Eli Lilly to sell low blood sugar drug to Amphastar for around $1 billion
▼ + stars: | 2023-04-24 | by ( ) www.reuters.com time to read: +1 min

April 24 (Reuters) - Amphastar Pharmaceuticals (AMPH.O) will buy Baqsimi from Eli Lilly and Co (LLY.N) in a deal worth up to $1.08 billion as it aims to boost its portfolio of low blood sugar drugs, the two companies said on Monday. Amphastar will pay $500 million at closing and another $125 million in cash after one year under the deal. Eli Lilly is also eligible to receive milestone payments of up to $450 million based on sales of Baqsimi, the only nasally administered drug to treat severely low blood sugar, or hypoglycemia, in people with diabetes. Launched in 2019, Baqsimi saw worldwide sales worth $139.3 million in 2022, the companies said. Other drugs that are used to treat low blood sugar in diabetes patients include Novo Nordisk's (NOVOb.CO) Zegalogue and GlucaGen and Xeris Pharmaceuticals' Gvoke HypoPen.

☆ Big Tech earnings, crucial inflation call — here comes the biggest week of earnings season
▼ + stars: | 2023-04-22 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Stocks stuck to a holding pattern this week as investors brace for an incoming wave of Big Tech earnings and the Fed's favorite inflation reading. Earnings reports have generally been better than expected so far this first quarter. Humana (HUM) reports before the bell Wednesday; Meta Platforms and Pioneer Natural Resources (PXD) report after the bell Wednesday. ET: Personal Spending & Income (includes PCE Price Index) Club trades this week Just one trade: We added 150 shares of Coterra Energy (CTRA) on Wednesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Lilly has not previously discussed its Medicare coverage optimism publicly. The U.S. Centers for Medicare & Medicaid Services (CMS) did not immediately respond to a request for comment. Such "coverage with evidence development" requirements are rare and historically used by Medicare to evaluate medical devices. Amyvid, Lilly's Alzheimer's imaging agent that can detect amyloid plaques on PET scans, has been subject to CMS' evidence development program for a decade. "It shuts out many patients," said Dr. Maria Carrillo, chief science officer of the Alzheimer’s Association, "especially minorities and rural patients."

☆ 'It totally backfired': The pitfalls of Alzheimer's genetic testing
▼ + stars: | 2023-04-21 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +8 min

CHICAGO, April 21 (Reuters) - Wendy Nelson watched her mother slowly die of Alzheimer's disease, unable to move or swallow at the end. When her father's memory began to fail a year later, one of her two sisters doubted it could be Alzheimer's, Nelson said. THE TESTING REVOLUTIONUntil recently, most doctors tended not to order genetic tests to determine Alzheimer's risk, because there were no effective treatments to slow or prevent the disease. US regulators recommend genetic testing before starting treatment with Leqembi. Some members of families with increased genetic risk of Alzheimer's say it might be better not to know at all.

☆ Eli Lilly jumps to all-time highs on Alzheimer's news. Here's what it means our investment
▼ + stars: | 2023-04-21 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

LLY 1Y mountain Shares of Eli Lilly over the past 12 months. Still, a commercially successful Alzheimer's drug would be material for Eli Lilly and strengthen its long-term position. Mounjaro is the heart of our Eli Lilly investment case. Another catalyst looming for Eli Lilly shares is results from a study conducted by its competitor in the weight-loss category Novo Nordisk . Eli Lilly Pharmaceutical company logo SOPA Images | LightRocket | Getty Images

☆ Eli Lilly to invest additional $1.6 bln in 2 new plants
▼ + stars: | 2023-04-17 | by ( ) www.reuters.com time to read: +1 min

April 17 (Reuters) - Eli Lilly and Co (LLY.N) said on Monday it will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, United States to support the manufacturing of its recently approved cancer drug, Jaypirca, among others. The company's total investment commitment in the facilities now stands at $3.7 billion, Eli Lilly said. The company in January announced plans to invest an additional $450 million to expand capacity of a plant in North Carolina and meet the strong demand for its blockbuster diabetes drug Trulicity and recently launched Mounjaro. Its commitments for expansion of the North Carolina site are $1.7 billion. Reporting by Leroy Leo in Bengaluru; Editing by Shinjini GanguliOur Standards: The Thomson Reuters Trust Principles.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Club meeting recap: Jim Cramer says stick with health care stocks in uncertain times
▼ + stars: | 2023-04-11 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Equities mixed Stick with health care Watch DHR, CAT 1. Stick with health care Health care is a stable sector to be in during times of economic uncertainty, Jim Cramer reiterated Tuesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Here are the 6 stocks we traded at the start of the second quarter — and why
▼ + stars: | 2023-04-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +6 min

But the first week of trading of the second quarter got off to a rocky start, forcing us to recalibrate our approach to the market. But as the week progressed, stocks came under pressure amid signs the labor market is softening, fueling fresh investor fears of a recession. That prompted many investors to dump technology stocks in favor of defensive sectors like health care and consumer staples. We plan to stick with these three oil stocks, given energy prices are likely to move even higher amid ongoing geopolitical turmoil. Thursday We ended the trading week by purchasing this automation-focused industrial giant on weakness.

☆ Jim Cramer's top 10 things to watch in the stock market Wednesday: New dawn for JNJ, Disney push, Meta upgrade
▼ + stars: | 2023-04-05 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Meta Platforms (META) price target raised to $250 from $225 at Jeffries. Federal Realty (FRT) price target lowered to $111 from $118 at Piper Sandler. Bank of America raises price target for Apple to $168 from $158, keeps a neutral rating on shares. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Club meeting recap: Jim Cramer says 'the existential threat is gone for J&J'
▼ + stars: | 2023-04-05 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer said Wednesday that J & J's proposal could mean, "the existential threat is gone for J & J." Watch Eli Lilly Club holding Eli Lilly (LLY) will report a key phase-3 data readout of its Alzheimer's drug Donanemab in the next one-to-two months. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Premarket stocks: These are the only stocks that matter right now
▼ + stars: | 2023-04-05 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +7 min

Leading the way in growth are tech stocks like Apple (AAPL), Microsoft (MSFT), Alphabet (GOOGL), Amazon (AMZN), Tesla (TSLA) and Meta (FB). That’s been a boon to large cap tech stocks that are more sensitive to interest rates because they tend to borrow more than established companies and rely more on the prospect of future earnings. But it also means that the current market rally is thin, as the major indexes outperform the average stock. Strong outperformance from the largest stocks often power indexes to rise, said Liz Ann Sonders, chief investment strategist at Schwab, in a note Tuesday. But healthy markets should be characterized by greater participation of the “soldiers” — the rest of the stocks, she said.

☆ Going against the grain: We're nibbling on weakness and selling into strength
▼ + stars: | 2023-04-04 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

We are buying 20 shares of Caterpillar (CAT) at roughly $217.39 and selling 20 shares of Eli Lilly (LLY) at roughly $355.11. With the market dumping the cyclicals and favoring the defensives today, we are going against the grain by nibbling on weakness (Caterpillar) and selling into strength (Eli Lilly). As for Eli Lilly, the recent rotation back into pharmaceutical stocks has pushed LLY back near $360, which is about where it started in 2023. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Lilly says experimental Alzheimer's drug reduces amyloid in small study
▼ + stars: | 2023-03-31 | by ( Deena Beasley | ) www.reuters.com time to read: +3 min

The higher the dose of the antibody drug, which was given by subcutaneous injection, the larger the effect, Lilly said. The Indianapolis-based drugmaker is launching a Phase III study of the experimental antibody, remternetug, but declined to comment on which doses will be selected for larger, later-stage trials. Lilly, at a medical conference in Gothenburg, Sweden, presented interim data from 41 study participants. Trial results published last year showed that, in patients with early Alzheimer's, Leqembi reduced the rate of cognitive decline by 27% compared with a placebo. Brooks said that sharing its early remternetug data "reinforces Lilly's commitment and investment in the Alzheimer's disease space ...

Stock Chart Icon Stock chart icon Nvidia's stock performance year to date. Stock Chart Icon Stock chart icon Meta's stock performance year to date. Stock Chart Icon Stock chart icon Devon Energy's stock performance year to date. Stock Chart Icon Stock chart icon Johnson & Johnson's stock performance year to date. Stock Chart Icon Stock chart icon Honeywell's year to date stock performance.

☆ As weight-loss drugs hit the U.S. market, doctors debate how to use them
▼ + stars: | 2023-03-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +6 min

[1/2] The American Medical Association logo is seen at their office in Washington, D.C., U.S., August 30, 2020. REUTERS/Andrew Kelly/March 30 (Reuters) - As powerful new obesity drugs enter the U.S. market, medical associations are keen to advise their members on how to best use them for patients. "These new compounds are game changers, there's no doubt about it," said Anthony Comuzzie, chief executive of The Obesity Society. The group last provided obesity treatment guidelines in 2013 alongside the American Heart Association and American College of Cardiology. OBESITY AS A DISEASEThe American Medical Association, the nation’s largest medical group, recognized obesity as a disease in 2013.

REUTERS/Daniel BecerrilLONDON, March 29 (Reuters) - Drugs that combat obesity could for the first time be included on the World Health Organization's "essential medicines list," used to guide government purchasing decisions in low- and middle-income countries, the U.N. agency told Reuters. A panel of advisers to the WHO will review new requests for drugs to be included next month, with an updated essential medicines list due in September. The request to consider obesity drugs was submitted by three doctors and a researcher in the United States. The majority – 70% - live in low- and middle-income countries. EXPANDING ACCESSIncluding obesity drugs among the WHO's essential medicines could have great significance for that population.

☆ Here's our March rapid-fire update on all 36 stocks in Jim Cramer's Investing Club portfolio
▼ + stars: | 2023-03-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +13 min

Here's a rapid-fire update on every stock in the CNBC Investing Club portfolio. But importantly, the chipmaker has joined Apple in rarified air, becoming an "own it, don't trade it" stock for the Club. The company's business can withstand an economic slowdown and benefits from a weaker U.S. dollar because of its large international presence. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Viking joins obesity drug race after promising early trial data
▼ + stars: | 2023-03-28 | by ( Mariam Esunny | ) www.reuters.com time to read: +2 min

March 28 (Reuters) - Viking Therapeutics Inc's (VKTX.O) experimental obesity drug helped reduce weight and was safe in an early-stage study, the company said on Tuesday, sparking a 60% rise in its shares. While Novo Nordisk (NOVOb.CO) already has its obesity drug, Wegovy, in the market, Eli Lilly is expecting approval for its treatment later this year. That could also make Viking a potential acquisition target, Laidlaw & Company analyst Yale Jen said. Viking said it was planning to test higher doses of the drug over a longer treatment window in a mid-stage trial, versus a shorter limit in the current, early-stage trial. Shares of Viking were trading at $14.15, bringing the drugmaker closer to a market capitalization of $1 billion.

☆ Novartis buoyed by trial success in early-stage breast cancer
▼ + stars: | 2023-03-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

The Swiss firm's shares jumped 5.8% on Monday to a four-week high by 0734 GMT, after it said a panel of independent supervisors recommended stopping the trial early because an interim analysis had shown a clear benefit. Kisqali has been approved to treat hormone-driven breast cancer that has spread to other body parts, where it has taken market share from Pfizer's (PFE.N) Ibrance. Rival drug Verzenio by Eli Lilly (LLY.N) has approval in the early setting for women at high risk of recurrence after surgery. Kisqali, which saw sales gain 31% to $1.2 billion last year, is one of two new drugs with a particularly important role for the group's future sales growth. Detailed trial results will be presented at a medical conference, Novartis said, without identifying the meeting or its timing.

Search resuls for: "LLY"

25 mentions found